ANAB

Analyst Note: ANAB (AnaptysBio, Inc.)

Date: 2026-06-12 Sector: Healthcare / Biotechnology

1. Structural Readiness

• Conservative Entry: $55.25 (Breakout level).
• Current Price: $57.51.
• Extension: +4.1% above the conservative entry.
• Volatility Context: The ATR at the time of the breakout was recorded at 6.1% (Very High), indicating a high-conviction structural move with elevated volatility. Current ATR is 5.8% (High), suggesting the volatility regime remains active but slightly compressed relative to the initial breakout impulse.

2. Thesis Layer

The primary secular thesis driving this setup is Biotech & GLP-1 → Immunology & Inflammation.

• Directness: AnaptysBio is a Tier Direct beneficiary. The company is not merely a supplier or a peripheral player; it is the originator of the intellectual property and the primary beneficiary of the royalty streams and milestone payments associated with its lead assets.
• Exposure: The company operates at the intersection of autoimmune disease treatment and the broader immunology sector. The separation of its commercial assets (Jemperli royalties) from its clinical-stage pipeline (rosnilimab, ANB033, ANB101) creates a dual-engine exposure: a cash-flowing royalty engine and a high-beta clinical-stage growth engine.
• Conviction Weighting: The combination of a secured, high-growth royalty stream (Jemperli) and a near-term catalyst pipeline (Phase 3 updates) provides a robust foundation for the "Quality Compounder" archetype. The direct exposure to the immunology theme is reinforced by the specific focus on autoimmune and inflammatory diseases in the spun-out entity.

3. Business Analysis

As of June 12, 2026, AnaptysBio operates as a clinical-stage biotechnology company focused on innovative therapeutics for autoimmune and inflammatory diseases. The business model has recently undergone a significant structural transformation via the separation of its commercial assets.

• Commercial Royalty Engine (Jemperli):
• Asset: Jemperli (dostarlimab), an immuno-oncology therapy.
• Partner: GlaxoSmithKline (GSK).
• Financials: As of March 31, 2026, the company's partner, Sagard, has received a total of $249.3 million in royalties and milestones.
• Growth: GSK reported $1.1 billion in sales for Jemperli for the year ended December 31, 2025, representing greater than 80% sales growth compared to $598.0 million in 2024.
• Royalty Structure: Under GSK Amendment No. 3, AnaptysBio is eligible for tiered royalties on net sales:
• 8% on sales below $1.0 billion.
• 12% on sales between $1.0 billion and $1.5 billion.
• 20% on sales between $1.5 billion and $2.5 billion.
• 25% on sales above $2.5 billion.
• Milestones: The company remains eligible for milestone payments if a European regulatory submission and approval in a second indication is achieved. The threshold for aggregate royalties and milestones to be received by Sagard is set at $600.0 million if received by March 31, 2031, or $675.0 million thereafter.

• Clinical Pipeline (Spun-Out Entity):
• Separation: The separation of the clinical-stage assets was completed on April 20, 2026.
• Focus: The spun-out company focuses on rosnilimab, ANB033, and ANB101 for autoimmune and inflammatory diseases.
• Rosnilimab (RA): Initial data from a randomized, placebo-controlled, global 424-patient Phase 2b trial for moderate-to-severe rheumatoid arthritis was announced in February 2025 and updated in June 2025. Management expects to provide an update on Phase 3 advancement in the first half of 2026.
• Imsidolimab (GPP): Vanda Pharmaceuticals submitted a BLA to the U.S. FDA for imsidolimab in GPP in December 2025. The FDA accepted the filing in February 2026, with a target action date of December 12, 2026.

• Capitalization: Upon completion of the separation, management intended to launch the clinical-stage company with adequate capital to fund operations for at least twelve months.

4. Archetype and Conviction

Archetype: Quality Compounder.

• Fit: The company fits the "Quality Compounder" archetype due to the transition from a pure-play clinical biotech to a hybrid model with a high-margin, recurring royalty revenue stream (Jemperli) and a de-risked, well-capitalized clinical pipeline. The 80% sales growth in the partner's Jemperli sales validates the commercial viability of the underlying asset, while the structured royalty escalators provide a leveraged upside to commercial success.
• Valuation & Financial Spine: The financial spine is supported by the "Collaboration revenue" recognized from milestones and royalties. The separation allows the market to value the royalty stream (cash flow) and the clinical assets (optionality) separately, potentially reducing the discount typically applied to pre-revenue biotechs.
• Conviction Stack:
• Thesis Strength: High. Direct exposure to a growing immunology market with a proven commercial partner.
• Evidence Quality: Strong. Multiple SEC filings (May 2026, March 2026) confirm the separation, financial milestones, and regulatory timelines.
• Structural Quality: High. The ATR at breakout (6.1%) indicates a "very high" structural quality move, suggesting strong institutional interest and momentum.
• Rerating Potential: Significant. The market may re-rate the company from a "clinical-stage risk" to a "commercial royalty + clinical optionality" hybrid, particularly as the Phase 3 update for rosnilimab approaches and the FDA decision for imsidolimab nears.

5. Invalidations, Strengths, and Gaps

• Invalidation Triggers:
• Failure to secure the Phase 3 advancement update for rosnilimab in the first half of 2026 (as of the current date, this is a management expectation that must be met).
• Any material adverse change in the GSK commercial performance or a breach of the royalty agreement terms.
• Strengthening Factors:
• Confirmation of the Phase 3 advancement for rosnilimab.
• Positive FDA decision on imsidolimab (target date Dec 12, 2026).
• Continued double-digit growth in Jemperli sales, pushing the company into higher royalty tiers (e.g., crossing the $1.5B or $2.5B thresholds).
• Gaps in Evidence:
• Post-Separation Financials: While the separation was completed in April 2026, specific pro-forma financial statements detailing the exact cash burn rate and runway of the *new* clinical-stage entity post-separation are not explicitly detailed in the provided evidence beyond the "adequate capital" statement.
• Detailed Pipeline Data: While Phase 2b data is cited, the specific efficacy metrics (e.g., ACR20/50/70 scores) for rosnilimab are not provided in the evidence block, limiting a granular assessment of the clinical probability of success.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key risks: Clinical trial failure for rosnilimab or imsidolimab; Regulatory delay or rejection by FDA for imsidolimab; GSK commercial performance stagnation reducing royalty tiers. Sizing hint: Position size should reflect the high ATR volatility (5.8-6.1%) but can be supported by the confirmed structural breakout and strong royalty floor. Expected path: Management expects to fund the clinical entity for 12 months post-separation; Phase 3 update for rosnilimab expected H1 2026; FDA decision for imsidolimab targeted Dec 2026. Expected horizon: 12 to 18 months for the Phase 3 update and FDA decision cycle to fully price in.